that could provide additional diagnostic information; and
2) understand the mitochondrial metabolism of glioma stem
cells (GSC), with a focus on IDH 1-2 gene polymorphism,
in collaboration with our Neuropathology Laboratory. More
recently, IECPN started a line of research on liquid biopsy,
with a network involving three different universities in Rio de
Janeiro. The objective is to compare the diagnostic accuracy of
this method to detect other tumors and gliomas.
In reference to teaching activities, the main initiative of our
group is the Neurocritical Care Post Graduate Course, which was
designed as a one-year (240-hour) program, coordinated by Dr.
Ricardo Turon and Dr. Darwin Prado and is now about to host our
second class of trainees. The course was developed for physicians
who work in the ICU and are looking for an in-depth knowledge
of neurocritical care. Since Brazil does not yet offer any formal
training in neurocritical care, our postgraduate course stands out
as a rare opportunity physicians have to specialize in the area
without leaving the country.
The opening of IECPN is definitely a milestone in the history of
Brazil’s public health. This visionary initiative has brought cutting
edge treatment and state-of-the-art technology to a great number
of patients who had never had access to private healthcare, as
well as forefront research in critical areas of neuroscience and
education for future generations of healthcare professionals
training in neurocritical care and neurosurgery.
Author’s Note: I would like to thank Dr Vivaldo Moreira Neto, Dr.
Leila Chimelli and Dr. Monica Gadelha for their contributions to this